44 related articles for article (PubMed ID: 26488798)
1. Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
[TBL] [Abstract][Full Text] [Related]
2. Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma.
Truong HL; Barreto JN; Mara KC; Hampel PJ; Micallef IN; Nowakowski GS; Thanarajasingam G; Thompson CA; Wang Y; Witzig TE; Herrmann SM; Leung N
JCO Oncol Pract; 2024 Jun; 20(6):797-807. PubMed ID: 38408299
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate level discrepancy post-glucarpidase: A pediatric case series and review of literature.
Kibby D; Trinkman H
Pediatr Blood Cancer; 2024 Mar; 71(3):e30831. PubMed ID: 38149827
[TBL] [Abstract][Full Text] [Related]
4. Late administration of glucarpidase in methotrexate intoxication: Do we have more time than we thought?
Miceli G; Daidone M; Corpora F; Gaudio FD; Tuttolomondo A;
Eur J Intern Med; 2024 Jan; 119():144-145. PubMed ID: 37806838
[No Abstract] [Full Text] [Related]
5. Early intervention is important when administering glucarpidase for methotrexate intoxication.
Bettini LR; Rizzari C
Eur J Intern Med; 2024 Feb; 120():118-119. PubMed ID: 38102037
[No Abstract] [Full Text] [Related]
6. Early intervention is important when administering glucarpidase for methotrexate intoxication. Author's reply.
Miceli G; Daidone M; Corpora F; Di Gaudio F; Tuttolomondo A;
Eur J Intern Med; 2024 Jun; 124():152-153. PubMed ID: 38685140
[No Abstract] [Full Text] [Related]
7. Comment on: A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials.
Meyers PA
Pediatr Blood Cancer; 2023 Nov; 70(11):e30617. PubMed ID: 37553477
[No Abstract] [Full Text] [Related]
8. A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials.
Janeway KA; Gros L; Schwartz S; Daugherty C; Gallardo E; Hill C; Thomas E; Ward S; Rizzari C
Pediatr Blood Cancer; 2023 Jun; ():e30506. PubMed ID: 37369988
[TBL] [Abstract][Full Text] [Related]
9. Reply to: Comment on: A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials.
Janeway KA; Gros L; Schwartz S; Daugherty C; Gallardo E; Hill C; Thomas E; Ward S; Rizzari C
Pediatr Blood Cancer; 2023 Dec; 70(12):e30662. PubMed ID: 37795968
[No Abstract] [Full Text] [Related]
10. Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available.
Rosales A; Madrid A; Muñoz M; Dapena JL; Ariceta G
Front Pediatr; 2021; 9():635152. PubMed ID: 34490152
[No Abstract] [Full Text] [Related]
11. Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Meyers PA
Pediatr Blood Cancer; 2016 Feb; 63(2):364. PubMed ID: 26488216
[No Abstract] [Full Text] [Related]
12. Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
Widemann BC
Pediatr Blood Cancer; 2015 Sep; 62(9):1512-3. PubMed ID: 25940351
[No Abstract] [Full Text] [Related]
13. The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity - a review of pharmacological and clinical data.
Kielbowski K; Rosik J; Bakinowska E; Gromowska E; Ustianowski Ł; Szostak B; Pawlik A
Expert Opin Drug Metab Toxicol; 2023; 19(11):741-750. PubMed ID: 37846862
[TBL] [Abstract][Full Text] [Related]
14. Glucarpidase treatment for methotrexate intoxication: a case report and review of the literature.
Boelens AD; Mathôt RAA; Vlaar APJ; Bouman CSC
Neth J Med; 2018 Jan; 76(1):36-39. PubMed ID: 29380731
[TBL] [Abstract][Full Text] [Related]
15. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Scott JR; Crews KR
Pediatr Blood Cancer; 2016 Feb; 63(2):365. PubMed ID: 26488798
[No Abstract] [Full Text] [Related]
16. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Widemann BC
Pediatr Blood Cancer; 2016 Feb; 63(2):366. PubMed ID: 26488622
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
